The Quad-Pathway

Archival Status

The Quad-Pathway protocol combines Retatrutide and Cagrilintide to engage four distinct satiety and metabolic axes simultaneously — GIP (glucose-dependent insulinotropic polypeptide), GLP-1 (glucagon-like peptide-1), Glucagon, and Amylin. This makes it the broadest mechanistic coverage available in peptide-based weight management research. Retatrutide is a triple agonist targeting GIP, GLP-1, and glucagon receptors. Clinical trial data from Phase 2 studies published in 2023 reported mean body weight reductions of 17.5% at 24 weeks at the highest dose — exceeding the clinical benchmarks set by dual agonists. The glucagon component adds a thermogenic dimension absent from semaglutide or tirzepatide monotherapy, increasing basal metabolic rate through hepatic glucose production modulation and brown adipose tissue activation. Cagrilintide is a long-acting amylin analogue that complements GLP-1 receptor agonists by engaging a separate satiety pathway. Amylin is co-secreted with insulin from pancreatic beta cells and works centrally in the hypothalamus and brainstem to slow gastric emptying, suppress glucagon secretion, and induce satiety independent of the GLP-1/GIP axis. Research combining cagrilintide with semaglutide (the CagriSema combination) demonstrated additive weight loss effects in Phase 3 trials, confirming the mechanistic independence of amylin signaling. When combined, Retatrutide and Cagrilintide create a four-pathway satiety system that addresses peripheral metabolism (GIP thermogenesis), hepatic glucose regulation (glucagon), intestinal transit and central satiety (GLP-1), and the independent amylin pathway (cagrilintide). This multi-axis approach is theorized to reduce compensatory mechanisms — the appetite rebound that often limits long-term efficacy of single-axis agents. This protocol is studied in contexts of severe obesity, metabolic syndrome, and type 2 diabetes management research. Due to the potency of both compounds, research protocols emphasize gradual titration to manage gastrointestinal tolerability. Both compounds require weekly or bi-weekly subcutaneous administration with careful glycemic monitoring when used in diabetic populations.